New Rezpegaldesleukin Data Shows Durable Responses in Atopic Dermatitis

Nektar Therapeutics' novel biologic demonstrates sustained disease control and deepening of responses over time.

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Nektar Therapeutics announced promising results from the 52-week REZOLVE-AD study of rezpegaldesleukin, a first-in-class regulatory T-cell (Treg) biologic, for the treatment of moderate-to-severe atopic dermatitis (AD). The data showed sustained disease control and even deepening of responses over time with both monthly and quarterly dosing regimens, potentially reshaping the treatment landscape for this chronic inflammatory skin condition.

Why it matters

Rezpegaldesleukin represents a novel approach to AD treatment, focusing on bolstering the body's natural regulatory T cells (Tregs) to restore immune balance, unlike existing therapies that broadly suppress the immune system. The positive long-term efficacy data suggests rezpegaldesleukin can provide continued improvement and durable control of the disease, offering hope for the millions of people affected by this chronic condition.

The details

The REZOLVE-AD Phase 2b study, involving 393 patients, revealed significant benefits with both monthly (Q4W) and quarterly (Q12W) maintenance dosing regimens. A substantial proportion of patients maintained EASI-75 responses (a 75% improvement in eczema severity) – 71% with monthly dosing and 83% with quarterly dosing. Similarly, vIGA-AD 0/1 responses (indicating clear or almost clear skin) were maintained by 85% and 63% of patients, respectively. Notably, the study showed a two- to five-fold increase in EASI-100 response rates – meaning complete skin clearance – in the 24 µg/kg dosing groups.

  • The REZOLVE-AD Phase 2b study was conducted over 52 weeks.
  • Nektar Therapeutics anticipates a potential Biologics License Application (BLA) submission in 2029.

The players

Nektar Therapeutics

A biopharmaceutical company that develops innovative medicines based on its proprietary polymer conjugate technology platforms.

Dr. Jonathan Silverberg

Professor of Dermatology at The George Washington University School of Medicine and Health Sciences.

Dr. David Rosmarin

Chair of Dermatology at Indiana University School of Medicine.

Got photos? Submit your photos here. ›

What they’re saying

“These data show that rezpegaldesleukin, as a broad-based Treg agonist, is emerging as one of the most important mechanisms in development to treat atopic dermatitis.”

— Dr. Jonathan Silverberg, Professor of Dermatology

“Importantly, we don't see any increased risk of incidence of conjunctivitis, oral herpes, oral ulcers or malignancies with this MOA as has been observed with other mechanisms.”

— Dr. David Rosmarin, Chair of Dermatology

What’s next

Nektar Therapeutics anticipates a potential Biologics License Application (BLA) submission for rezpegaldesleukin in 2029 following the completion of pivotal Phase 3 clinical trials evaluating both monthly and quarterly maintenance dosing.

The takeaway

Rezpegaldesleukin's unique approach of targeting regulatory T cells to restore immune balance could offer a much-needed alternative for atopic dermatitis patients who have not found relief with existing therapies, potentially providing sustained disease control and improved quality of life.